Clinical Trials Logo

Diabetes Mellitus, Type 2 clinical trials

View clinical trials related to Diabetes Mellitus, Type 2.

Filter by:

NCT ID: NCT05820295 Active, not recruiting - Stroke Clinical Trials

Improving How Older Adults at Risk for Cardiovascular Outcomes Are Selected for Care Coordination

Start date: May 17, 2023
Phase: N/A
Study type: Interventional

This pragmatic clinical trial embedded in an accountable care organization will determine the comparative effectiveness of two approaches for assigning care coordinators to older adults at risk for cardiovascular outcomes. The hypothesis is that assigning care coordinators to older adults based on perceived need will be more effective at preventing emergency department visits and hospitalizations compared to usual care.

NCT ID: NCT05819749 Active, not recruiting - Clinical trials for Diabetes Mellitus, Type 2

Diabetes Homelessness Medication Support Program in Spanish

DH-Spanish
Start date: May 1, 2023
Phase: N/A
Study type: Interventional

This single-arm trial of the Diabetes Homeless Medication Support intervention for Spanish-speaking people (n=12) will test the perception and feasibility of anticipated study procedures.

NCT ID: NCT05793788 Active, not recruiting - Cancer Clinical Trials

UCLA Health Patient Health Maintenance Outreach Text Message

Start date: March 9, 2023
Phase: N/A
Study type: Interventional

This is a prospective randomized clinical trial evaluating how behaviorally-informed outreach text messages impact patient engagement with primary care. This prospective randomized control trial is being implemented in conjunction with UCLA Health's larger quality improvement initiative (the My Action Plan Quality Improvement Initiative) in order to improve primary care preventive measure completion rates.

NCT ID: NCT05791955 Active, not recruiting - Cancer Clinical Trials

UCLA Health Patient Health Maintenance With Interactive Text Reminder

Start date: May 23, 2023
Phase: N/A
Study type: Interventional

This is a prospective randomized clinical trial evaluating how behaviorally-informed outreach text message reminders impact patient engagement with primary care. This prospective randomized control trial is being implemented in conjunction with UCLA Health's larger quality improvement initiative (the My Action Plan Quality Improvement Initiative) in order to improve primary care preventive measure completion rates.

NCT ID: NCT05791942 Active, not recruiting - Cancer Clinical Trials

UCLA Health Patient Health Maintenance Text Reminder

Start date: March 23, 2023
Phase: N/A
Study type: Interventional

This is a prospective randomized clinical trial evaluating how behaviorally-informed outreach text message reminders impact patient engagement with primary care. This prospective randomized control trial is being implemented in conjunction with UCLA Health's larger quality improvement initiative (the My Action Plan Quality Improvement Initiative) in order to improve primary care preventive measure completion rates.

NCT ID: NCT05786521 Active, not recruiting - Clinical trials for Diabetes Mellitus, Type 2

Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults

Start date: April 1, 2023
Phase: Phase 4
Study type: Interventional

Semaglutide is a medication approved by the US Food and Drug Administration (FDA) as an antihyperglycemic (a drug that reduces glucoses in those with diabetes) and for weight management. This new study will help find out what effects, semaglutide has on people who take the drug and the drug's effect on physical function, body composition, and aging.

NCT ID: NCT05784220 Active, not recruiting - Diabetes type2 Clinical Trials

The Canadian Diabetes Prevention Program

CDPP
Start date: June 21, 2019
Phase: N/A
Study type: Interventional

According to Diabetes Canada ("DC"), in 2015, the estimated prevalence of prediabetes in Canada (>20 years of age) is 5.7 million people (22.1%). This rate is estimated to increase to 6.4 million people (23.2%) by 2025. Risk factors contributing to prediabetes and consequently Type 2 Diabetes include rising obesity rates, lack of physical activity, an aging population, and the cultural diversity of Canada . There is convincing evidence that modifiable risk factors, such as diet and physical activity reduce the development of Type 2 Diabetes with the benefits extending beyond the active intervention stage. The underlying theory that supports this intervention relates to the imperative need to focus on weight loss and physical activity, with this population that is at risk of developing diabetes, due to its relationship with insulin resistance. DC outlines the importance of intensive and structured lifestyle modification to promote weight loss in order to reduce the progression of prediabetes to diabetes.

NCT ID: NCT05780151 Active, not recruiting - Clinical trials for Diabetes Mellitus, Type 2

Remote And Decentralised Innovative Approaches to Clinical Trials (RADIAL)

RADIAL
Start date: July 10, 2023
Phase: Phase 4
Study type: Interventional

Pan-European proof-of-concept study comparing Decentralised Clinical Trial (DCT) and hybrid approaches to conventional clinical trial approaches in patients with Type 2 diabetes mellitus treated with Toujeo®.

NCT ID: NCT05768945 Active, not recruiting - Diabetes Clinical Trials

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors

Start date: November 30, 2022
Phase:
Study type: Observational

This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.

NCT ID: NCT05764629 Active, not recruiting - Diabetes Mellitus Clinical Trials

An Observational Study on Post-chronic Pancreatitis Diabetes Mellitus

Start date: September 1, 2021
Phase:
Study type: Observational

To explore the risk factors influencing glycemic status, optimized treatment, and prognosis of post-chronic pancreatitis diabetes mellitus (PPDM-C).